NCT05840484Recruiting
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-specific and overall outcomes..
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 11 Apr 2023
- Start date
- 29 Mar 2023
- Primary completion date
- 30 Jul 2029
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT05840484
What you commit to
- Study type: Observational
- Planned participants: 100
- From 29 Mar 2023 to the primary completion date, 30 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation therapy for treatment of the primary tumor.
- Planned concomitant hormonal therapy, chemotherapy, or radiation therapy while on protocol
Other
- Patients are ineligible if they choose not to share their medical data for research purposes.
Who the study is looking for
- Patients will have histologic diagnosis of adenocarcinoma of the prostate within 24 months of study entry.
- Patient must meet at least one of the following clinical indications for AS: National Comprehensive Cancer Network (NCCN) very low risk or low risk prostate cancer meeting consensus guidelines for AS; NCCN intermediate-risk prostate cancer requesting AS (per patient and clinician shared decision making); or have severe medical comorbidities (defined as CCI estimated 10-year survival \< 50% and agreed by treating clinician) with high- or very high-risk localized prostate cancer.
- Patients must agree to comply with the surveillance schedule.
- Patients must be over 18 years of age
- Written informed consent
- Patients must be fluent in the English language to participate in the patient report outcome and symptoms monitoring portion of the trial.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.